LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special…
<!-- Name:DistributionId Value:8836929 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
LianBio
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating…
<!-- Name:DistributionId Value:8825727 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with…
SHANGHAI, China and PRINCETON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and…
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese…
• LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) --…
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Completed enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong…
U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of…
SHANGHAI and PRINCETON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration…
LianBio Announces Formation of Scientific Advisory Board
SHANGHAI, China and PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and…